Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.53 |
| ▸ | MC3R | P41968 | 3/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | MC1R | Q01726 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14356073 | 1.00 | MC4R (0.53) | MC4RMC3RMC5RMC1R | |
| SCHEMBL5336019 | 1.00 | MC4R (0.53) | MC4RMC3RMC5RMC1R | |
| Hydrochloric Acid SCHEMBL5335857 | 0.99 | MC4R (0.52) | MC4RMC3RMC5RMC1R | |
| Hydrochloric Acid SCHEMBL5335859 | 0.99 | MC4R (0.52) | MC4RMC3RMC5RMC1R | |
| SCHEMBL14356074 | 0.89 | MC4R (0.48) | MC4RMC3RMC5RMC1R | |
| SCHEMBL5336132 | 0.89 | MC4R (0.48) | MC4RMC3RMC5RMC1R | |
| Hydrochloric Acid SCHEMBL5338106 | 0.88 | MC4R (0.48) | MC4RMC3RMC5RMC1R | |
| SCHEMBL14356082 | 0.80 | MC4R (0.51) | MC4RMC3RMC5R | |
| SCHEMBL14356076 | 0.80 | MC4R (0.51) | MC4RMC3RMC5R | |
| SCHEMBL14355929 | 0.79 | MC4R (0.58) | MC4RMC3RMC5RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | MC4R 2/4885MC3R 4/4885MC5R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.